UK Drug Update, September 2002

Published: 22-Aug-2002
Regulatory


Goldshield has brought out Komil 5/40 tablets containing 40mg of the loop diuretic frusemide and 5mg of the potassium-sparing diuretic amiloride hydrochloride.

Link Pharmaceuticals has made available Tranquilyn tablets containing 5mg, 10mg or 20mg of the CNS stimulant methylphenidate hydrochloride.

APS/Berk has introduced 250mg, 500mg and 750mg tablets of the antibiotic ciprofloxacin.

Roche Products has marketed Pegasys injection. The product contains 180µg/0.5ml of the immuno-stimulating agent peginterferon a-2a in a prefilled syringe.

Merck Sharp & Dohme has launched Caspofungin infusion containing 50mg or 70mg of the antimycotic agent caspofungin (as acetate).

GlaxoSmithKline has introduced a live attenuated varicella-zoster vaccine, under the name of Varilrix.

Lagap Pharmaceuticals has added to its range of generics: 10mg tablets of cetirizine dihydrochloride; co-zidocapt tablets in two strengths: with 25mg of the ACE inhibitor captopril and 12.5mg of the thiazide diuretic hydrochlorothiazide, and with 50mg captopril plus 25mg hydrochlorothiazide; 5mg tablets of warfarin; and 5mg and 10mg tablets of the hypnotic zolpidem tartrate.

See more

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

Read more
New SOLAR CEMNEX analyser offers advanced compliance and connectivity features

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision

Partnership delivers compliance confidence, efficiency gains and reduced waste
Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Subscribe now